Advertisement

Rheumatoid Arthritis and ‘Popper Sequences’

  • Alan Ebringer
Chapter

Abstract

The cause of rheumatoid arthritis has been investigated by the methods of Sir Karl Popper who claimed that a theory could not be proved by induction or any other methods but could be disproved.

A fact which was incompatible with a theory would thereby disprove it and this approach has provided a powerful new method to investigate scientific problems.

Keywords

Rheumatoid Arthritis Urinary Tract Infection Rheumatoid Arthritis Patient Molecular Mimicry Popper Sequence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Avakian H, Welsh J, Ebringer A, Entwistle CC. Ankylosing spondylitis, HLA-B27 and Klebsiella. II. Cross-reactivity studies with human tissue typing sera. Br J Exp Pathol. 1980;61:92–6.PubMedGoogle Scholar
  2. Avorn J, Monane M, Gurwitz JH, Glynn RJ, Chodnovskiy I, Lipsitz LA. Reduction of bacteriuria and pyuria after ingestion of cranberry juice. JAMA. 1994;271:751–4.PubMedCrossRefGoogle Scholar
  3. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic, literature review. Ann Rheum Dis. 2006;65:845–51.PubMedCrossRefGoogle Scholar
  4. Blankenberg-Sprenkels SHD, Fielder M, Feldkamp TEW, Tiwana H, Wilson C, Ebringer A. Antibodies to Klebsiella pneumoniae in Dutch patients with ankylosing spondylitis and acute anterior uveitis and to Proteus mirabilis in rheumatoid arthritis. J Rheumatol. 1998;25:743–7.PubMedGoogle Scholar
  5. Deighton CM, Gray SW, Biant AJ, Walker DJ. Specificity of the Proteus antibody response in rheumatoid arthritis. Ann Rheum Dis. 1992;51:1206–7.PubMedCrossRefGoogle Scholar
  6. Ebringer A, Ptaszynska T, Corbett M, Wilson C, Macafee Y, Avakian H, et al. Antibodies to Proteus in rheumatoid arthritis. Lancet. 1985;2:305–7.PubMedCrossRefGoogle Scholar
  7. Ebringer A, Cox NL, Abuljadayel I, Ghuloom M, Khalafpour S, Ptaszynska T, et al. Klebsiella antibodies in ankylosing spondylitis and Proteus antibodies in rheumatoid arthritis. Br J Rheumatol. 1988;27(Suppl II):72–85.PubMedGoogle Scholar
  8. Ebringer A, Rashid T, Wilson C. Rheumatoid arthritis: proposal for the early use of anti-bacterial therapy. Scand J Rheumatol. 2003;32:2–11.PubMedCrossRefGoogle Scholar
  9. Ebringer A, Rashid T, Wilson C. Rheumatoid arthritis, Proteus, anti-CCP antibodies and Karl Popper. Autoimmun Rev. 2010;9:216–23.PubMedCrossRefGoogle Scholar
  10. Fielder M, Tiwana H, Youinou P, Le Goff P, Deonarian R, Wilson C, et al. The specificity of the anti-Proteus antibody response in tissue-typed rheumatoid arthritis (RA) patients from Brest. Rheumatol Int. 1995;15:79–82.PubMedCrossRefGoogle Scholar
  11. Khalafpour S, Ebringer A, Abuljadayel I, Corbett M. Antibodies to Klebsiella and Proteus microrganisms in ankylosing spondylitis and rheumatoid arthritis patients measured by ELISA. Br J Rheumatol. 1988;27(Suppl II):86–9.PubMedGoogle Scholar
  12. Newkirk MM, Goldbach-Mansky R, Senior BW, Klippel J, Schumacher Jr HR, El-Gabalawy HS. Elevated levels of IgM and IgA antibodies to Proteus mirabilis and IgM antibodies to Escherichia coli are associated with early rheumatoid factor (RF)-positive rheumatoid arthritis. Rheumatology. 2005;44:1433–41.PubMedCrossRefGoogle Scholar
  13. Nymand G. Maternal smoking and immunity. Lancet. 1974;2:1379–80.PubMedCrossRefGoogle Scholar
  14. O’Dell JR, Paulsen G, Haire CE, Blakely K, Palmer W, Wees S, et al. Treatment of early seropositive rheumatoid arthritis with minocycline. Arthritis Rheum. 1999;42:1691–5.PubMedCrossRefGoogle Scholar
  15. Rashid T, Ebringer A. Rheumatoid arthritis is linked to Proteus – the evidence. Clin Rheumatol. 2007a;26:1036–43.PubMedCrossRefGoogle Scholar
  16. Rashid T, Jayakumar KS, Binder A, Ellis S, Cunningham P, Ebringer A. Rheumatoid arthritis patients have elevated antibodies to cross-reactive and non-cross reactive antigens from Proteus microbes. Clin Exp Rheumatol. 2007b;25:259–67.PubMedGoogle Scholar
  17. Rashid T, Leirisalo-Repo M, Tani Y, Hukuda S, Kobayashi S, Wilson C, et al. Antibacterial and antipeptide antibodies in Japanese and Finnish patients with rheumatoid arthritis. Clin Rheumatol. 2004;23:134–41.PubMedCrossRefGoogle Scholar
  18. Schellekens GA, de Jong BA, Van den Hoogen FH, Van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis specific auto-antibodies. J Clin Invest. 1998;101:273–81.PubMedCrossRefGoogle Scholar
  19. Subair H, Tiwana H, Fielder M, Binder A, Cunningham K, Ebringer A, et al. Elevation in anti-Proteus antibodies in patients with rheumatoid arthritis from Bermuda and England. J Rheumatol. 1995;22:1825–8.PubMedGoogle Scholar
  20. Tani Y, Tiwana H, Hukuda S, Nishioka J, Fielder M, Wilson C, et al. Antibodies to Klebsiella, Proteus and HLA-B27 peptides in Japanese patients with ankylosing spondylitis and rheumatoid arthritis. J Rheumatol. 1997;24:109–14.PubMedGoogle Scholar
  21. Tiwana H, Wilson C, Cunningham P, Binder A, Ebringer A. Antibodies to four gram-negative bacteria in rheumatoid arthritis which share sequences with the rheumatoid arthritis susceptibility motif. Br J Rheumatol. 1996;35:592–4.PubMedCrossRefGoogle Scholar
  22. Tiwana H, Wilson C, Walmsley RS, Wakefield AJ, Smith MSN, Cox NL, et al. Antibody responses to gut bacteria in ankylosing spondylitis, rheumatoid arthritis, Crohn’s disease and ulcerative colitis. Rheumatol Int. 1997;17:11–6.PubMedCrossRefGoogle Scholar
  23. Vital EM, Emery P. The development of targeted therapies in rheumatoid arthritis. J Autoimmun. 2008;31:219–27.PubMedCrossRefGoogle Scholar
  24. Wanchu A, Deodhar SD, Sharma M, Gupta V, Bambery P, Sud A. Elevated levels of anti-Proteus antibodies in patients with active rheumatoid arthritis. Indian J Med Res. 1997;105:39–42.PubMedGoogle Scholar
  25. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy. Arthritis Rheum. 2007;56:2886–95.PubMedCrossRefGoogle Scholar
  26. Zintzaras E, Dahabreh LJ, Giannouli S, Voulgarelis M, Moutsopoulos HM. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. Clin Ther. 2008;30:1939–55.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2011

Authors and Affiliations

  • Alan Ebringer
    • 1
  1. 1.King’s College London Division of Life SciencesUCH School of MedicineLondonUK

Personalised recommendations